mos Health (COSM) - 2025 Q3 - Quarterly Results

Financial Performance - Q3 2025 revenue reached $17.11 million, a 38% increase from $12.41 million in Q3 2024, marking an all-time high[4] - Gross profit for Q3 2025 was $2.60 million, up 116% from $1.21 million in Q3 2024, the highest quarterly gross profit in company history[4] - Gross margin expanded to a record 15.21%, an improvement of 549 basis points from 9.72% a year earlier[4] - Adjusted EBITDA loss improved 74% to ($0.19 million) in Q3 2025 from ($0.70 million) in Q3 2024[4] Financial Position - Cash position increased to $4.63 million from $0.66 million as of June 30, 2025, reflecting significant improvement in financial flexibility[10] - Total assets rose to $69.49 million, up from $61.84 million as of June 30, 2025, indicating enhanced liquidity and a diversified asset base[10] - Total assets increased to $69.49 billion as of September 30, 2025, up from $61.84 billion in June 2025, representing a growth of 12.7%[20] - Accounts receivable rose to $25.95 billion, a 11.2% increase from $23.36 billion in June 2025[20] - Inventory increased to $5.68 billion, up 11.2% from $5.11 billion in June 2025[20] - Total liabilities reached $46.36 billion, compared to $43.79 billion in June 2025, marking a 5.9% increase[20] - Stockholders' equity decreased to $23.13 billion from $26.18 billion in June 2025, a decline of 11.7%[20] Growth Initiatives - The company secured a $300 million digital financing facility to support growth initiatives and digital asset investments[10] - A contract manufacturing agreement was signed with Medical Pharmaquality for the production of 3 million MYCOFAGYL pessaries annually, expanding the pharmaceutical portfolio[10] - U.S. operations for the Sky Premium Life brand commenced, with all products manufactured locally in GMP-certified facilities[10] - The company expanded Sky Premium Life across the GCC region, entering Oman with an exclusive distribution agreement and an initial purchase order of 42,000 units[10] - The company is expanding its global distribution platform across Europe, Asia, and North America, enhancing its market presence[21] Strategic Partnerships and Acquisitions - Cosmos Health has entered the telehealth sector through the acquisition of ZipDoctor, Inc., broadening its service offerings[21] - The company is focusing on R&D partnerships targeting major health disorders, leveraging AI for drug repurposing technologies[21] - Cosmos Health's product portfolio includes proprietary pharmaceutical and nutraceutical brands, indicating a diversified business model[21] Financing and Risk Management - The company emphasizes the importance of securing financing to implement its business plan amid various risks and uncertainties[22]